within Pharmacolibrary.Drugs.ATC.L;

model L04AJ09
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 0.1,
    adminDuration  = 600,
    adminMass      = 0.1,
    adminCount     = 1,
    Vd             = 0.06,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.008333333333333333,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Danicopan is an orally administered, selective oral factor D inhibitor developed as a complement pathway inhibitor, primarily for use in paroxysmal nocturnal hemoglobinuria (PNH) and other complement-mediated disorders. It is not approved by the FDA or EMA as of 2024 but has been investigated in clinical trials for PNH, including as add-on therapy to C5 inhibitors for patients with extravascular hemolysis.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated based on phase I and II clinical trial publications and limited publicly available data regarding healthy adult subjects after oral administration.</p><h4>References</h4><ol><li><p>Risitano, AM, et al., &amp; Browett, P (2021). Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria. <i>Haematologica</i> 106(12) 3188–3197. DOI:<a href=&quot;https://doi.org/10.3324/haematol.2020.261826&quot;>10.3324/haematol.2020.261826</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33121236/&quot;>https://pubmed.ncbi.nlm.nih.gov/33121236</a></p></li><li><p>Kulasekararaj, AG, et al., &amp; Brodsky, RA (2021). Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab. <i>Blood</i> 138(20) 1928–1938. DOI:<a href=&quot;https://doi.org/10.1182/blood.2021011388&quot;>10.1182/blood.2021011388</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34314483/&quot;>https://pubmed.ncbi.nlm.nih.gov/34314483</a></p></li><li><p>Versino, F, &amp; Fattizzo, B (2024). Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapy. <i>International journal of laboratory hematology</i> 46 Suppl 1 43–54. DOI:<a href=&quot;https://doi.org/10.1111/ijlh.14281&quot;>10.1111/ijlh.14281</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38622956/&quot;>https://pubmed.ncbi.nlm.nih.gov/38622956</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L04AJ09;
